Press release
August 14, 2026
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Quince Therapeutics, Inc. (QNCX)
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline LAM-001 Phase 2b data in PH-ILD anticipated in the first quarter of 2028; Phase 2 data in BOS anticipated in the first